SCHEMBL15537663

SCHEMBL15537663

CN(c1ccc(-c2ccc(C(=O)O)c(F)c2)cc1)C1CCN(CC(C)(C)F)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 2/20 0.42
RARB P10826 3/20 0.40
RARA P10276 2/20 0.40
RARG P13631 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
CYP3A4 P08684 1/20 0.39
OPRM1 P35372 1/20 0.38
PDK2 Q15119 2/20 0.37
DYRK1A Q13627 3/20 0.37
WNT1 P04628 2/20 0.37
GSK3B P49841 1/20 0.37
MCHR1 Q99705 2/20 0.37
ACHE P22303 1/20 0.36
KCNH2 Q12809 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
UBE2M P61081 1/20 0.36
DCUN1D1 Q96GG9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15539847 0.88 PKM (0.41) CHRM4CHRM2CHRM5CHRM1CHRM3
SCHEMBL15538492 0.85 CYP3A4 (0.43) CHRM4CYP3A4OPRM1MCHR1
SCHEMBL15537666 0.79 CHRM4 (0.47) CHRM4RARBRARARARGCHRM2
SCHEMBL15538445 0.79 RARA (0.51) CHRM4RARBRARACHRM2CHRM5
SCHEMBL15538435 0.78 CHRM4 (0.42) CHRM4CYP3A4OPRM1MCHR1GPR119
SCHEMBL15538448 0.77 CHRM4 (0.43) CHRM4RARBRARACHRM2CHRM5
SCHEMBL15540335 0.77 OPRM1 (0.40) CHRM4CYP3A4OPRM1PDK2MCHR1
SCHEMBL21534846 0.76 CHRM4 (0.44) CHRM4RARBRARARARGCHRM2
SCHEMBL15540323 0.74 HDAC4 (0.48) PDK2MCHR1
SCHEMBL15538426 0.74 DYRK1A (0.43) CHRM4RARBRARACHRM2CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2858986-B1 PIPERIDINE DERIVATIVES AS GPR119 AGONISTS CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2019-10-30 EP disclosed
US-9944600-B2 Piperidine derivatives for GPR119 agonist CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2018-04-17 US disclosed
US-20150166480-A1 PIPERIDINE DERIVATIVES FOR GPR119 AGONIST CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2015-06-18 US disclosed
EP-2858986-A1 PIPERIDINE DERIVATIVES FOR GPR119 AGONIST Chong Kun Dang Pharmaceutical Corp. (KR) 2015-04-15 EP disclosed
WO-2013187646-A1 PIPERIDINE DERIVATIVES FOR GPR119 AGONIST CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2013-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166480-A1 PIPERIDINE DERIVATIVES FOR GPR119 AGONIST GPR119, FFAR2, GPR84 CHRM4 669/4885RARB 707/4885RARA 825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.